235 related articles for article (PubMed ID: 37528416)
21. A missense SNP in the tumor suppressor SETD2 reduces H3K36me3 and mitotic spindle integrity in Drosophila.
Brockett JS; Manalo T; Zein-Sabatto H; Lee J; Fang J; Chu P; Feng H; Patil D; Davidson P; Ogan K; Master VA; Pattaras JG; Roberts DL; Bergquist SH; Reyna MA; Petros JA; Lerit DA; Arnold RS
Genetics; 2024 Apr; 226(4):. PubMed ID: 38290049
[TBL] [Abstract][Full Text] [Related]
22. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
Li L; Miao W; Huang M; Williams P; Wang Y
Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
[TBL] [Abstract][Full Text] [Related]
23. SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.
Zhou X; Sekino Y; Li HT; Fu G; Yang Z; Zhao S; Gujar H; Zu X; Weisenberger DJ; Gill IS; Tulpule V; D'souza A; Quinn DI; Han B; Liang G
Cancer Res; 2023 Nov; 83(22):3813-3826. PubMed ID: 37695044
[TBL] [Abstract][Full Text] [Related]
24. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
25. A New Chromatin-Cytoskeleton Link in Cancer.
Giaccia AJ
Mol Cancer Res; 2016 Dec; 14(12):1173-1175. PubMed ID: 27528705
[TBL] [Abstract][Full Text] [Related]
26. SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.
Fahey CC; Davis IJ
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159833
[TBL] [Abstract][Full Text] [Related]
27. SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer.
Rao H; Liu C; Wang A; Ma C; Xu Y; Ye T; Su W; Zhou P; Gao WQ; Li L; Ding X
Nat Commun; 2023 Nov; 14(1):7572. PubMed ID: 37989747
[TBL] [Abstract][Full Text] [Related]
28. SETD2-dependent H3K36me3 plays a critical role in epigenetic regulation of the HPV31 life cycle.
Gautam D; Johnson BA; Mac M; Moody CA
PLoS Pathog; 2018 Oct; 14(10):e1007367. PubMed ID: 30312361
[TBL] [Abstract][Full Text] [Related]
29. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.
Carvalho S; Vítor AC; Sridhara SC; Martins FB; Raposo AC; Desterro JM; Ferreira J; de Almeida SF
Elife; 2014 May; 3():e02482. PubMed ID: 24843002
[TBL] [Abstract][Full Text] [Related]
30. Cancer-driving H3G34V/R/D mutations block H3K36 methylation and H3K36me3-MutSα interaction.
Fang J; Huang Y; Mao G; Yang S; Rennert G; Gu L; Li H; Li GM
Proc Natl Acad Sci U S A; 2018 Sep; 115(38):9598-9603. PubMed ID: 30181289
[TBL] [Abstract][Full Text] [Related]
31. Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation.
Rajagopalan KN; Chen X; Weinberg DN; Chen H; Majewski J; Allis CD; Lu C
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619101
[TBL] [Abstract][Full Text] [Related]
32. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
33. Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.
Feng W; Ma C; Rao H; Zhang W; Liu C; Xu Y; Aji R; Wang Z; Xu J; Gao WQ; Li L
Cancer Lett; 2023 Nov; 579():216470. PubMed ID: 37914019
[TBL] [Abstract][Full Text] [Related]
34. Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond.
Skucha A; Ebner J; Grebien F
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818762
[TBL] [Abstract][Full Text] [Related]
35. Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Zhou Y; Zheng X; Xu B; Deng H; Chen L; Jiang J
Aging (Albany NY); 2020 Nov; 12(24):25189-25206. PubMed ID: 33223508
[TBL] [Abstract][Full Text] [Related]
36. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Martinelli G; Mancini M; De Benedittis C; Rondoni M; Papayannidis C; Manfrini M; Meggendorfer M; Calogero R; Guadagnuolo V; Fontana MC; Bavaro L; Padella A; Zago E; Pagano L; Zanotti R; Scaffidi L; Specchia G; Albano F; Merante S; Elena C; Savini P; Gangemi D; Tosi P; Ciceri F; Poletti G; Riccioni L; Morigi F; Delledonne M; Haferlach T; Cavo M; Valent P; Soverini S
Leukemia; 2018 Jan; 32(1):139-148. PubMed ID: 28663576
[TBL] [Abstract][Full Text] [Related]
37. SETD2 regulates the methylation of translation elongation factor eEF1A1 in clear cell renal cell carcinoma.
Hapke R; Venton L; Rose KL; Sheng Q; Reddy A; Prather R; Jones A; Rathmell WK; Haake SM
Kidney Cancer J; 2022; 6(3):179-193. PubMed ID: 36684483
[TBL] [Abstract][Full Text] [Related]
38. The SETD2 Methyltransferase Supports Productive HPV31 Replication through the LEDGF/CtIP/Rad51 Pathway.
Mac M; DeVico BM; Raspanti SM; Moody CA
J Virol; 2023 May; 97(5):e0020123. PubMed ID: 37154769
[TBL] [Abstract][Full Text] [Related]
39. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
40. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
